title: Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.
abstract: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder caused by damage of motoneurons leading to paralysis state and long term disability. Riluzole is currently the only FDA-approved drug for the treatment of ALS. The proposed mechanisms of ALS include glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, SOD1 accumulations, and neuronal death. In this review, we discuss potential biomarkers for the identification of patients with ALS. We further emphasize potential therapy involving the uses of neurotrophic factors such as IGFI, GDNF, VEGF, ADNF-9, colivelin and angiogenin in the treatment of ALS. Moreover, we described several existing drugs such as talampanel, ceftriaxone, pramipexole, dexpramipexole and arimoclomol potential compounds for the treatment of ALS. Interestingly, the uses of stem cell therapy and immunotherapy are promising for the treatment of ALS.
authors.forename: G
authors.initials: G
authors.lastname: Yacila
authors.affiliation: University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology, Health Science Campus, 3000 Arlington Avenue, Toledo, OH 43614. USA. youssef.sari@utoledo.edu.
authors.forename: Y
authors.initials: Y
authors.lastname: Sari
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy / Q000628:therapy*; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D064987:Cell- and Tissue-Based Therapy; D004195:Disease Models, Animal; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D009414:Nerve Growth Factors / Q000627:therapeutic use; D019782:Riluzole / Q000627:therapeutic use; D033581:Stem Cell Transplantation
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D009414:Nerve Growth Factors; D019782:Riluzole